Patent · US Expired

Synergistic neutralization of HIV-1 by human monoclonal antibodies and other antibodies directed against the v3 loop and the CD-4 binding site of GP-120,and the use for immunotherapy of HIV-1 infection

US5922325A · kind A · utility

10Cited by

5References

53Claims

0Family size

Assignee

The Public Health Research Institute Of the City of New York, Inc. · US

Inventors

Shermaine A. Tilley · New York, US
Abraham Pinter · Brooklyn, US

Key dates

Filing date	May 22, 1995
Grant date	Jul 13, 1999
Priority date	—
Expiry date	May 22, 2015

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16122
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A synergistic combination of antibodies specific for HIV envelope glycoprotein gp120 is described. One of the antibodies specific for the V3 loop and the other is specific for the CD-4 binding site of gp120.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.